News Search Results
Nov 21, 2025, 08:04 ET SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
fatal events in 0.2%. The most frequent neurologic toxicities were dysgeusia (34%), headache (17%), peripheral neuropathy (9%), dizziness (9%), and insomnia (8%). The incidence of signs and symptoms consistent with ICANS was 10% in IMDELLTRA®-treated patients including events with the preferred
More news about: Amgen
Nov 19, 2025, 09:00 ET Insomnia Cookies Marks 350 Locations in Ongoing Global Expansion
Download Insomnia Cookies images here. About Insomnia Cookies Insomnia Cookies is a category-disrupting late-night
More news about: Insomnia Cookies
Nov 18, 2025, 08:00 ET Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide.
More news about: Lipocine Inc.
Nov 17, 2025, 08:04 ET SK Life Science, Inc. Announces Publication of C035 Study Analyses in Epilepsia and Seizure
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
Nov 13, 2025, 16:18 ET How to Talk to Your Doctor about CBD
of Medicine's comprehensive biomedical literature database. Start with broad terms like "cannabidiol" or "CBD," and refine with specifics such as insomnia, anxiety, aching joints, addiction. Filter for "clinical trials," "case reports," or "systematic reviews" to find specific types of evidence. Systematic
More news about: Fusion CBD Products
Nov 13, 2025, 10:15 ET Ingenus Pharmaceuticals Announces FDA Approval and Launch of First and Only Generic Equivalent to Premarin® Tablets (Conjugated Estrogens Tablets, USP)
levels. Most common adverse reactions (≥ 5 percent) are abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis. Please see full
More news about: Ingenus Pharmaceuticals LLC
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
meaningful changes on ophthalmic exams in the alixorexton-treated group. The most common TEAEs4,5 were pollakiuria, insomnia, urinary urgency, dizziness and headache. Approximately 95% of patients completed the eight-week double-blind portion of
More news about: Alkermes plc
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
meaningful changes on ophthalmic exams in the alixorexton-treated group. The most common TEAEs4,5 were pollakiuria, insomnia, urinary urgency, dizziness and headache. Approximately 95% of patients completed the eight-week double-blind portion of
More news about: Alkermes plc
Nov 12, 2025, 05:00 ET VISTAJET LAUNCHES THE SLEEP PROGRAM -- A SCIENCE-BACKED APPROACH TO REST AND RECOVERY AT ALTITUDE AND AT DESTINATION
performance to transform rest in-flight into a restorative advantage. As research continues to show that over one-third of adults experience insomnia[1] and over half experience poor sleep quality[2], VistaJet addresses a true demand for supportive travel solutions,
More news about: VistaJet
Nov 11, 2025, 16:24 ET Empower Mental Health & Wellness Clinic Opens Doors in Kenosha: Offering Mental Health Treatment and Physical Therapy
pain. As part of its launch, Empower will offer EXOMIND TMS, a noninvasive intervention to treat depression, reduce anxiety and food cravings, treat insomnia, and improve cognition and overall wellness.
More news about: Empower Mental Health & Wellness Clinic
Nov 10, 2025, 06:00 ET Headspace for Cigna Healthcare Enhances Everyday Mental Health Support Through Self-Guided, Science Backed Resources
depression symptoms after just 30 days. Participants in the Headspace Sleep Program also reported a 29% reduction in insomnia symptoms among adults with clinical, self-reported insomnia. Headspace and Cigna Healthcare will collaborate to develop custom content exclusively for Cigna customers.
More news about: Cigna Healthcare
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, rash, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, musculoskeletal pain, upper respiratory tract infection, peripheral
More news about: Johnson & Johnson
Nov 04, 2025, 09:00 ET Kong Releases Insomnia 12 to Accelerate API and MCP Development with AI-Powered Testing and Collaboration
cloud API and AI technologies, announced today the general availability of Insomnia 12, the open source API development platform that unifies designing, mocking, debugging, and testing APIs. The new release focuses on making Insomnia smarter, faster, and more accessible for developers building APIs and Model
More news about: Kong Inc.
Oct 29, 2025, 13:49 ET Marquez Medical Aesthetic Showcasing EXOMIND Technology for Mental and Physical Health
Oct. 29, 2025 /PRNewswire/ -- Individuals seeking a noninvasive treatment for depression, anxiety, obsessive-compulsive disorder, insomnia and brain fog may benefit from EXOMIND, a new brain stimulation treatment now available at Marquez Medical Aesthetic in Hialeah. Research shows EXOMIND
More news about: Marquez Medical Aesthetic
Oct 22, 2025, 08:00 ET Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
stomach (abdominal) pain diarrhea difficulty sleeping (insomnia) back pain hot flashes or hot flushes These are
More news about: Astellas Pharma Inc.
Oct 20, 2025, 21:20 ET SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Biopharmaceuticals. Co., Ltd.
Oct 20, 2025, 08:00 ET Elektra Health and Oscar Launch HelloMeno the First-Ever Menopause Health Plan in the Individual Market
$0 primary doctor, gynecologist, and behavioral health visits. No-cost labs, hormone replacement therapy, insomnia medications, and bone density scans. 24/7 access to Elektra and a team of doctors who know menopause inside and out2
More news about: Elektra Health
Oct 17, 2025, 08:00 ET Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting
(defined as AHI <5 events/hour) AD109 was generally well-tolerated, with the most common adverse events being dry mouth, insomnia and nausea, and no treatment-related serious adverse events were reported Select
More news about: Apnimed, Inc.
Oct 14, 2025, 20:00 ET Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
stomach (abdominal) pain diarrhea difficulty sleeping (insomnia) back pain hot flashes or hot flushes These are
More news about: Astellas Pharma Inc.
Oct 10, 2025, 07:30 ET Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
integrating mental and general health care.12 Insomnia is one of the most common symptoms of MDD, affecting more than 80 percent of people living with MDD.13 Disturbed sleep and insomnia symptoms have a significant impact on a patient's quality of life and exacerbate
More news about: Johnson & Johnson
Oct 07, 2025, 10:40 ET Melatonin Market to Reach USD 3.0 Billion by 2030 as Sleep Health, Supplements, and Clinical Applications Drive Global Demand
Dietary supplements accounted for USD 1.1 billion in 2025, making them the largest revenue driver. Melatonin supplements are widely consumed for insomnia, jet lag, and sleep management, particularly in North America and Asia. Medical industry applications
More news about: DataM Intelligence 4 Market Research LLP
Oct 06, 2025, 08:34 ET Menoveda Announces U.S. Launch
75% of them will experience a range of unpleasant symptoms, from hot flashes to hair loss, anxiety, fatigue, mood swings, insomnia, and brain fog. Menoveda helps alleviate those symptoms, filling a massive and unmet gap in women's health in the process. "We're
More news about: Menoveda
Oct 01, 2025, 07:45 ET Curaleaf and The Baldwin Fund Partner to Raise Funds for Breast Cancer Research This October
cannabis is not a treatment for cancer, some people living with breast cancer report that cannabis products can help them manage pain, nausea, anxiety, insomnia, and other side effects of treatment. Curaleaf is committed to providing safe, high-quality cannabis options for patients and consumers navigating
More news about: Curaleaf Holdings, Inc.
Sep 30, 2025, 09:00 ET The ADDF's Diagnostics Accelerator Unveils SpeechDx Dataset and New Partnership to Catalyze Breakthroughs in Speech-Based Biomarkers
mental health disorders, as Alzheimer's disease shares many overlapping symptoms with those conditions, such as depression, cognitive decline, and insomnia. Together, we will accelerate the development of tools that can make a real difference in patients' lives."
More news about: Alzheimer's Drug Discovery Foundation